A systematic review and economic model of the effectiveness and ...
A systematic review and economic model of the effectiveness and ...
A systematic review and economic model of the effectiveness and ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
68<br />
Clinical <strong>effectiveness</strong><br />
overactivity was measured using <strong>the</strong> IOWA-C,<br />
except when assessed by parents. No significant<br />
differences between <strong>the</strong>se two treatment arms were<br />
reported for global <strong>effectiveness</strong> (parent or teacher<br />
rated).<br />
Adverse events<br />
There were no significant differences between<br />
treatments in <strong>the</strong> incidence <strong>of</strong> headache, stomach<br />
ache, loss <strong>of</strong> appetite or insomnia. No data on<br />
weight were reported.<br />
Summary<br />
No studies in this category evaluated hyperactivity<br />
or CGI as outcomes. One study that reported<br />
adverse events data found no differences between<br />
<strong>the</strong> treatment groups.<br />
TABLE 53 MPH medium dose (15–30 mg/day) versus DEX low dose (